Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric H Rubin

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Cancer Research|January 21, 2006
Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathwayShyamal D Desai, Arthur L Haas, Laurence M Wood, et al.
Cancer|February 2, 2012
A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumorsCaio M Rocha-Lima, Soley Bayraktar, Jessica Macintyre, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2013
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancerTaofeek K Owonikoko, Joseph Aisner, Xin Victoria Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2019
Challenges with Novel Clinical Trial Designs: Master ProtocolsMichael Cecchini, Eric H Rubin, Gideon M Blumenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancerPamela N Munster, Eric H Rubin, Simon Van Belle, et al.
Anti-Cancer Drugs|May 6, 2008
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemiaBiren Saraiya, Murugesan Gounder, Jayeeta Dutta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxelGerald J Fetterly, Thaddeus H Grasela, Jeffrey W Sherman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trialRoy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancerEric H Rubin, Nancy G B Agrawal, Evan J Friedman, et al.
Cancer Chemotherapy and Pharmacology|October 19, 2005
A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignanciesDale Schaar, Lauri Goodell, Joseph Aisner, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Cancer Research|January 21, 2006
Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathwayShyamal D Desai, Arthur L Haas, Laurence M Wood, et al.
Cancer|February 2, 2012
A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumorsCaio M Rocha-Lima, Soley Bayraktar, Jessica Macintyre, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2013
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancerTaofeek K Owonikoko, Joseph Aisner, Xin Victoria Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2019
Challenges with Novel Clinical Trial Designs: Master ProtocolsMichael Cecchini, Eric H Rubin, Gideon M Blumenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancerPamela N Munster, Eric H Rubin, Simon Van Belle, et al.
Anti-Cancer Drugs|May 6, 2008
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemiaBiren Saraiya, Murugesan Gounder, Jayeeta Dutta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxelGerald J Fetterly, Thaddeus H Grasela, Jeffrey W Sherman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trialRoy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancerEric H Rubin, Nancy G B Agrawal, Evan J Friedman, et al.
Cancer Chemotherapy and Pharmacology|October 19, 2005
A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignanciesDale Schaar, Lauri Goodell, Joseph Aisner, et al.
Pageof 7